Notice: Prescription Drug List (PDL): Multiple Additions (2020-12-21)

Notice: Prescription Drug List (PDL): Multiple Additions (2020-12-21) The purpose of this Notice of Amendment is to notify about the additions of fostamatinib, givosiran, lemborexant, luspatercept, ozanimod, trientine, and voretigene neparvovec to the Prescription Drug List (PDL) for human and veterinary use. 2023-10-01 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetynotice of amendmentPrescription Drug ListPDLhuman-and-veterinary usefostamatinibgivosiranlemborexantluspaterceptozanimodtrientineand voretigene neparvovec. Notice: Prescription Drug List (PDL): Multiple Additions (2020-12-21)HTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2020-12-21.html Notice: Prescription Drug List (PDL): Multiple Additions (2020-12-21)HTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/additions-multiples-2020-12-21.html

The purpose of this Notice of Amendment is to notify about the additions of fostamatinib, givosiran, lemborexant, luspatercept, ozanimod, trientine, and voretigene neparvovec to the Prescription Drug List (PDL) for human and veterinary use.

Data and Resources

Similar records